

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 May 2025 (22.05.2025)



(10) International Publication Number
WO 2025/106761 A1

(51) International Patent Classification:

C07K 14/575 (2006.01) A61P 3/10 (2006.01)
A61P 3/06 (2006.01) A61K 38/00 (2006.01)

(21) International Application Number:

PCT/US2024/056046

(22) International Filing Date:

15 November 2024 (15.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/600,468 17 November 2023 (17.11.2023) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly
Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **ABRAHAM, Milata Mary**; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **ALSINA-FERNANDEZ, Jorge**; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **HILLIARD, Darryl Wayne**; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **KEYSER, Samantha Grace Lyons**; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **LIU, Wen**; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **QU, Hongchang**; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **SLUKA, Kristi Lynn**; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agent: **FULLER, Megan** et al.; c/o ELI LILLY AND COMPANY, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

WO 2025/106761 A1

(54) Title: COMPOUNDS FOR THE TREATMENT OF DIABETES OR OBESITY

(57) Abstract: The present disclosure relates to novel urocortin-2 polypeptides, having activity at the corticotropin-releasing hormone receptor-2 (CRHR2), pharmaceutical compositions comprising the polypeptides, and methods of using the polypeptides to treat disorders associated with CRHR2.